FindTrial
Sign In

A randomized phase 2 trial of Irinotecan/Paclitaxel versus Irinotecan/Gemcitabine in patient with stage IIIB/IV non small cell lung cancer.

A randomized phase 2 trial of Irinotecan/Paclitaxel versus Irinotecan/Gemcitabine in patient with stage IIIB/IV non small cell lung cancer.

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080220109
Enrollment
Unknown
Registered
2005-09-13
Start date
2005-09-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung cancer(NSCLC)

Interventions

investigational material(s) Generic name etc : Irinotecan (CPT-11) INN of investigational material : Therapeutic category code : 424 Antineoplastic preparations extracted from plants Dosage and Admin

Sponsors

Yakult Honsha Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Histologically confirmed NSCLC Neither prior chemotherapy nor prior radiotherapy Age between 20 and 74 years old ECOG Performance Status: 0-1

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Best overall response—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026